Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC.RVPH · Entity 8147 | Director | December 18, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Report date December 18, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2035-12-17 | Direct | 8,200 |
Reported balance
After 2025-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-18 · Grant · Acquired 8,200 · Balance 8,200 F1: This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share ("Common Stock"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share ("Common Stock"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Applied Therapeutics, Inc.
Report date December 19, 2025 · Filed February 03, 2026
Section 16 reporting ended · disclosed 2026-02-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-02-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-12-19 · Grant · Acquired 1,187,500 · Balance 2,527,959 F1: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date. Row 2 · 2026-02-03 · Disposition to issuer · Disposed 2,375,000 · Balance 152,959 F2: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. Row 3 · 2026-02-03 · Other · Disposed 152,959 · Balance 0 F2: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F4: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-03 · Disposition to issuer · Disposed 20,460 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-03 · Disposition to issuer · Disposed 10,230 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-03 · Disposition to issuer · Disposed 16,500 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-03 · Disposition to issuer · Disposed 16,500 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-03 · Disposition to issuer · Disposed 150,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-03 · Disposition to issuer · Disposed 40,502 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date.
F2: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.
F4: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.
F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2020 Filed Jun 25, 2020 21:45 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 200 | $36.12 | $7,224.00 |
DisclosureSEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 9 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,765 F9 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9600 to $36.2700 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 21:45 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 400 | $40.92 | $16,368.00 |
DisclosureSEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 8 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,965 F8 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $40.8300 to $40.9900 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 21:45 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 3,811 | $40.41 | $154,002.51 |
DisclosureSEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 7 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,365 F7 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $39.7700 to $40.7500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 21:45 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 3,572 | $39.20 | $140,022.40 |
DisclosureSEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 6 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,176 F6 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $38.7600 to $39.7500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:45 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 1,340 | $47.40 | $63,516.00 |
DisclosureSEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 5 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,748 F5 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $47.0900 to $48.0600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:45 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 160 | $46.45 | $7,432.00 |
DisclosureSEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 4 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,088 F4 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $46.0900 to $47.0500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:45 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 1,809 | $45.35 | $82,038.15 |
DisclosureSEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 3 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,248 F3 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $45.0000 to $45.8500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:45 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 3,462 | $44.54 | $154,197.48 |
DisclosureSEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 2 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,057 F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0000 to $44.9900 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 21:45 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 4,629 | $43.32 | $200,528.28 |
DisclosureSEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 1 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,519 F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $43.0000 to $43.7300 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:47 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-20-038359 · doc4.xml · derivative · entry 4 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,502 Underlying: Common Stock · 20,000 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options became fully vested on May 28, 2019. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:47 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 20,000 | $4.70 | $94,000.00 |
DisclosureSEC source: 0001209191-20-038359 · doc4.xml · nonDerivative · entry 3 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 21:47 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 11 | $45.90 | $504.90 |
DisclosureSEC source: 0001209191-20-038359 · doc4.xml · nonDerivative · entry 2 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,148 Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 21:47 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 7,487 | $45.32 | $339,310.84 |
DisclosureSEC source: 0001209191-20-038359 · doc4.xml · nonDerivative · entry 1 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,159 F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $44.8000 to $45.7800 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 4,100 | $44.15 | $181,015.00 |
DisclosureSEC source: 0001209191-20-037485 · doc4.xml · nonDerivative · entry 4 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,646 F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0000 to $44.5000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 100 | $45.18 | $4,518.00 |
DisclosureSEC source: 0001209191-20-037485 · doc4.xml · nonDerivative · entry 3 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,746 Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 5,302 | $44.37 | $235,249.74 |
DisclosureSEC source: 0001209191-20-037485 · doc4.xml · nonDerivative · entry 2 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,846 F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0000 to $44.9900 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-20-037485 · doc4.xml · derivative · entry 5 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,502 Underlying: Common Stock · 17,000 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options became fully vested on May 28, 2019. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 17,000 | $4.70 | $79,900.00 |
DisclosureSEC source: 0001209191-20-037485 · doc4.xml · nonDerivative · entry 1 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 2,563 | $42.83 | $109,773.29 |
DisclosureSEC source: 0001209191-20-035769 · doc4.xml · nonDerivative · entry 6 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,148 F5 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $42.3500 to $43.2400 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 2,622 | $41.80 | $109,599.60 |
DisclosureSEC source: 0001209191-20-035769 · doc4.xml · nonDerivative · entry 5 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,711 F4 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $41.3200 to $42.2800 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 1,500 | $44.87 | $67,305.00 |
DisclosureSEC source: 0001209191-20-035769 · doc4.xml · nonDerivative · entry 4 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,333 F3 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $44.5000 to $45.5000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 2,000 | $42.82 | $85,640.00 |
DisclosureSEC source: 0001209191-20-035769 · doc4.xml · nonDerivative · entry 3 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,833 F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $42.5500 to $42.9700 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-20-035769 · doc4.xml · derivative · entry 7 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,502 Underlying: Common Stock · 17,000 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These options became fully vested on May 28, 2019. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 8,315 | $44.77 | $372,262.55 |
DisclosureSEC source: 0001209191-20-035769 · doc4.xml · nonDerivative · entry 2 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,833 F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $44.5400 to $45.1700 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 17,000 | $4.70 | $79,900.00 |
DisclosureSEC source: 0001209191-20-035769 · doc4.xml · nonDerivative · entry 1 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2020 Filed Jun 4, 2020 21:25 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (Right to Buy) · Derivative | 10,230 | $0.00 Strike: $44.02 | $0.00 |
DisclosureSEC source: 0001209191-20-034593 · doc4.xml · derivative · entry 6 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,230 Underlying: Common Stock · 10,230 shares Expires 2030-06-03 F5 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 4, 2020 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| June 04, 2020 Filed Jun 4, 2020 21:25 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 1,482 | $44.17 | $65,459.94 |
DisclosureSEC source: 0001209191-20-034593 · doc4.xml · nonDerivative · entry 4 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,148 F3 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0000 to $44.5400 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 21:25 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 1,032 | $44.03 | $45,438.96 |
DisclosureSEC source: 0001209191-20-034593 · doc4.xml · nonDerivative · entry 3 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,630 F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0100 to $44.1100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:25 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-20-034593 · doc4.xml · derivative · entry 5 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,502 Underlying: Common Stock · 15,000 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options became fully vested on May 28, 2019. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:25 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 12,486 | $45.21 | $564,492.06 |
DisclosureSEC source: 0001209191-20-034593 · doc4.xml · nonDerivative · entry 2 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,662 F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $45.0000 to $45.7500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:25 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 15,000 | $4.70 | $70,500.00 |
DisclosureSEC source: 0001209191-20-034593 · doc4.xml · nonDerivative · entry 1 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 8,495 | $45.08 | $382,954.60 |
DisclosureSEC source: 0001209191-20-033313 · doc4.xml · nonDerivative · entry 4 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,148 F3 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $44.6800 to $45.5900 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 7,120 | $44.27 | $315,202.40 |
DisclosureSEC source: 0001209191-20-033313 · doc4.xml · nonDerivative · entry 3 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,643 F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $43.6200 to $44.6100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,453 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-20-033313 · doc4.xml · derivative · entry 5 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,453 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options became fully vested on April 22, 2019. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 2,838 | $48.27 | $136,990.26 |
DisclosureSEC source: 0001209191-20-033313 · doc4.xml · nonDerivative · entry 2 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,763 F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $48.0000 to $48.4800 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 18,453 | $0.04 | $738.12 |
DisclosureSEC source: 0001209191-20-033313 · doc4.xml · nonDerivative · entry 1 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:36 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (right to buy) · Derivative | 20,460 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001209191-19-034754 · doc4.xml · derivative · entry 1 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,460 Underlying: Common Stock · 20,460 shares Expires 2029-06-02 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the Option shall vest each month commencing on July 3, 2019, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 16, 2019 Filed May 20, 2019 17:05 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | ConversionSeries B Preferred Stock · Derivative | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031447 · doc4.xml · derivative · entry 4 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. Read SEC document |
| May 16, 2019 Filed May 20, 2019 17:05 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | ConversionSeries A Preferred Stock · Derivative | 3,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031447 · doc4.xml · derivative · entry 3 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,314 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. Read SEC document |
| May 16, 2019 Filed May 20, 2019 17:05 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | ConversionCommon Stock | 1,325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-031447 · doc4.xml · nonDerivative · entry 2 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. Read SEC document |
| May 16, 2019 Filed May 20, 2019 17:05 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | ConversionCommon Stock | 3,314 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-031447 · doc4.xml · nonDerivative · entry 1 Funtleyder Leslie D. · CIK 0001775394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.